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Abstract 
Background: The aim of this study is to determine the effect of hypoxia on axitinib and sorafenib-treated renal cell 
carcinoma (RCC) cells. Hypoxia is a crucial factor influencing transcription process via protein modulation, which was 
shown i.e. in pancreatic cancer. Until now, hypoxia has been defined as associated with poorer outcome and inducing 
chemotherapy resistance in solid tumors. The unique phenomenon of pseudo-hypoxia connected with vhl mutation 
was observed in clear-cell, but not in papillary RCC, and the treatment of this subtype of cancer is still challenging. 
Despite the introduction of new antiangiogenic targeted therapies (inter alia tyrosine kinase inhibitors, TKIs), patients 
still develop both primary and acquired resistance. Overcoming resistance to TKIs, also in papillary RCC, may be pos-
sible by finding significantly modified protein expression. To do this, hypoxic 3D in vitro models must be developed to 
mimic both molecular pathways typical for low oxygen tension and cell–cell dynamics in tumor-like spatial structures.
Results: Clear-cell and papillary renal cell carcinoma (cc and pRCC) cell lines were used in the study to determine the 
impact of hypoxia on primary drug resistance phenomenon previously observed in papillary, but not in ccRCC. Resist-
ance was confirmed in monolayer culture and in 3D models in soft agar and suspension culture. Human papillary 
kidney cancer stem-like cells (HKCSCs) cultured in hypoxia developed resistance to sorafenib, while when cultured in 
normoxia resistance to axitinib has developed. Flow cytometry revealed that hypoxia decreased proliferation rates in 
all investigated RCC cells. In HKCSCs, there was an increase of quiescent cells (Ki67−) and percentage of cells arrested 
in S phase. It also appeared that map2k1 and eif4b protein expression is altered in papillary RCC resistant to tested 
drugs at different oxygen tensions. Also, HKCSCs did not express vegfr-1, braf nor c-kit, TKIs target receptors, which 
were present in ccRCC cells sensitive to TKI treatment.
Conclusions: The results confirm that low oxygen tension affects RCC cells. Hypoxia facilitates induction of sorafenib 
resistance in pRCC and induces map2k1 overexpression, while normoxic axitinib-resistant cells up-regulated eif4b. 
Further studies may determine if map2k1 or eif4b proteins play a role in pRCC resistance to TKIs. It is also of interest to 
establish if other than vegfr-1, braf, c-kit receptors can serve as potential molecular targets for more effective anti-RCC 
strategies.
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Background
Renal cancers accounted for 3–5% of all malignancies in 
the adult population of the United States in 2013; 90–95% 
of kidney neoplasms are renal cell carcinomas (RCCs). 
Although initially RCC was believed to represent a uni-
form malignant phenotype, it is now known that it con-
stitutes a diverse group of cancers arising from the kidney 
tubule [1]. Clear cell (ccRCC), papillary (pRCC) and 
chromophobe (chRCC) reflect the main histological sub-
types of RCC [1–3]. RCC subtypes are defined by specific 
genetic abnormalities including von Hippel Lindau (vhl), 
hepatocyte growth factor receptor (c-met), Birt-Hogg-
Dubé (bhd) and fumarate hydratase (fh) gene mutations, 
which was confirmed in both classical genetics and in 
genomic studies [2, 4, 5]. Proliferative activity of all RCC 
cells, regardless of its subtype, is dependent on constitu-
tive activation of receptor tyrosine kinases (RTKs). These 
RTKs are targeted primarily by tyrosine kinase inhibi-
tors (TKIs)—sorafenib, sunitinib, pazopanib, axitinib or 
cabozantinib [6, 7]. Response to targeted therapies varies 
in its effectiveness and among RCC subtypes [8]. For the 
purposes of this study, several TKIs widely used in RCC 
treatment according to newest ESMO guidelines [9], 
were chosen: sunitinib, which binds 73 kinases in addi-
tion to its main target, vegfr-2; sorafenib, which binds 40 
additional kinases; and axitinib, which is the most selec-
tive, with a limited number of targets, mostly vegfr [10].
Sunitinib is primarily a potent inhibitor of vegfr-1, 
vegfr-2 (vascular endothelial growth factor receptors 1 
and 2), flt-3 (FMS-related tyrosine kinase 3), c-kit (also 
called cd117—stem cell factor receptor/proto-oncogene 
c-kit), pdgfrα and pdgfrβ (platelet-derived growth factor 
receptors). It inhibits the growth of cancer cell lines stim-
ulated by vegf, scf (skp, cullin, f-box containing complex), 
or pdgf and induces apoptosis [11, 12].
Like sunitinib, sorafenib inhibits activity of vegfr2 and 
vegfr3 but not vegfr-1, flt-3, c-kit and pdgfr [13]. It has 
been shown that sorafenib decreases tumor cell pro-
liferation via raf-1 (as well as wild-type braf and v599e 
braf) inhibition and that it effectively blocks the raf/mek/
erk signaling pathway in cancer cells [14]. It is also clear 
that sorafenib inhibits cancer cell proliferation in a dose-
dependent manner and induces cancer cell apoptosis as 
previously shown in the hepatocellular carcinoma (HCC) 
or leukemia models [14, 15]. Sorafenib was further shown 
to induce endothelial cells’ apoptosis in tumors. Thus, a 
dual inhibitor of raf kinase and vegfrs targets both cancer 
cells proliferation and cancer angiogenesis [13, 16].
Axitinib is a more selective second-generation inhibi-
tor of vegf-1, 2, and 3, pdgfrβ and c-kit [10]. Although 
axitinib is mostly known as an inhibitor of endothelial 
cell survival and new tube formation as well as an inhibi-
tor of protein kinase B (pkb, akt), nitric oxide (NO), and 
extracellular signal-regulated kinase (erk) signaling in 
endothelial cells [17]. It has also been shown that axitinib 
exerts direct cytotoxic activity against cancer cells. In 
cancer cells, axitinib inhibits cell growth and viability in a 
dose-dependent manner, causing a  G2/M cell-cycle arrest 
[18, 19]. Axitinib also blocks wnt/β-catenin signaling 
in cancer cells [20]. It was also shown to inhibit prolif-
eration of patient-derived glioblastoma cancer stem cells 
[21] and was used in potential myxoma virus-based treat-
ment directed against brain tumor-initiating cells [22].
Although these tyrosine kinase inhibitors have been 
applied to clinical settings, and their usability is still 
developing, the underlying molecular mechanisms 
behind anti-tumor activity remain unclear. Precise 
knowledge of up- and downregulated proteins in TKI-
treated cells as well as of TKIs’ in vitro effect in normoxia 
and hypoxia may help maximize treatment efficacy.
Until now, hypoxia has been defined as associated with 
poorer outcome and inducing chemotherapy resistance 
when present in solid tumors. Moreover, it has been 
shown that hypoxia does not necessarily act via hypoxia 
inducible factors—associated pathways [23]. Interest-
ingly, hypoxia but not normoxia was shown to modulate 
transcription process via protein upregulation in pan-
creatic cancer [24]. Therefore, our primary aim in this 
research was to evaluate the effect of hypoxia on TKI-
treated renal cancer cells of various histopathological ori-
gin, including papillary RCC.
Today, research in drug resistance research occurs in 
the most rapidly evolving areas of solid tumor molecular 
oncology research [25], however, the impact of hypoxia 
on renal cancer cells with primary resistant cell subpopu-
lations has not been fully characterized in any RCC cell 
culture bio-mimic model until today, also not in a 3D cell 
culture hypoxic model [26]. 3D cell culture models bet-
ter mimic in vivo conditions [27]. Moreover, cell growth 
dimensionality is strictly related to oxygen status. Path-
ologically relevant cell culture models in proper oxygen 
tension are required to study the complex physical and 
chemical processes by which the cancer microenviron-
ment mediates drug resistance [25]. Understanding these 
processes is especially significant because the hypoxia 
signaling pathway is frequently de-regulated in clear-cell 
renal cell carcinoma due to vhl mutations [28–30] and 
limited information is available on intratumoral hypoxia-
mediated signaling abnormalities in pRCC or ccRCC. In 
most hypoxia signaling studies, nephrectomy samples are 
analyzed [31] and only hypoxia inducible factors (hifs) 
mRNA levels are investigated [32], but no functional 
data is available. Hypoxia must be further investigated to 
explain efficacy of TKI treatment in RCC.
Therefore, the secondary aim of this study is to ana-
lyze TKI response in low oxygen tension in clear-cell and 
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non-clear cell RCCs and in human kidney cancer stem 
cells.
Until today, sorafenib has been recognized as more 
effective in oxygenated (normoxic) environments [33]. 
In adherent monolayer 2D cell cultures, sorafenib inhib-
its viability of 786-O ccRCC cells under normoxia more 
effectively than in hypoxia. In 2D cell culture, hypoxia 
promotes 786-O cells resistance to sorafenib and its 
invasiveness. Hif-2α and cox-2 signaling pathways were 
shown to be responsible for this phenomenon [34]. 
Moreover, the ACHN cell line was shown to be generally 
sensitive to hypoxia, characterized by slower prolifera-
tion and subsequent resistance to sorafenib (anti-cancer, 
anti-proliferative activity) [33]. At the same time, Caki-1 
and 786-O cells expressing wild type vhl—compared to 
Caki-2 and 786-O mutant vhl cells—were shown to be 
twofold more resistant to the anti-proliferative effects 
of sorafenib under hypoxic conditions. No difference in 
resistance was observed under normoxic conditions [35]. 
Taking this into account, our tertiary goal is to compare 
TKI response in hypoxic and normoxic conditions in a 
3D culture model.
All steps of the study—(1) RCC cells TKI response, 
(2) human papillary kidney cancer cells (HKCSCs) drug 
resistance, and (3) TKI response in different oxygen ten-
sion—represent one spectrum of co-dependent phe-
nomena. The ultimate aim of this study is to explain 
how hypoxia affects TKIs direct impact on renal cancer 
cells and how low oxygen tension and cancer cell–cell 
interactions in 3D structures modulate RCC tyrosine 
kinase inhibitors’ resistance. Understanding the hypoxia-
induced RCC TKI-resistant phenotype is crucial to 
develop novel in  vitro study models for testing targeted 
therapies.
Throughout the article, we use several abbreviations for 
human papillary renal cancer cells (HKCSCs), which dur-
ing the study: (1) developed resistance to axitinib in nor-
moxia—those are marked rAN; (2) developed resistance 
to sorafenib in hypoxia—those are marked rSH; (3) 
remained sensitive to axitinib in hypoxia (i.e. were sen-
sitized)—marked sAH; (4) remained sensitive (i.e. sensi-
tized) to sorafenib in normoxia—marked sSN, (5) were 
untreated in normoxia—N, and (6) were untreated in 
hypoxia—H. These abbreviations comprise only HKC-
SCs’ cell line, since none of other cell lines used in the 
study developed TKI-mediated resistance and thus were 
not further investigated. Cells were compared either 
in one oxygen tension group, i.e. only normoxic vs only 
hypoxic samples, or in one treatment group regardless 
of oxygen tension, i.e. axitinib resistant and sensitized 
vs untreated, etc. The mechanism of cells comparison is 
presented on Fig. 1.
Methods
Cell lines
Each cell line was obtained directly from a cell bank that 
performs individual cell line characterization. After deliv-
ery, cells were sub-cultured after the first passage for sev-
eral stocks, which have been used in further years. The 
stocks used in this research were independently de-fro-
zen in 2014–2015 and used for no more than 6 months.
HKCSCs have been originally obtained from a single 
donor diagnosed with papillary RCC; the cell line was 
obtained from Celprogen Inc. (Cat. No. 36117-44) and 
primarily cultured in monolayer in a medium recom-
mended by the producer: Human kidney cancer stem 
cell complete medium with serum and antibiotics (Cel-
progen, Inc., Cat. No. M36117-44S) and passaged using 
a trypsin/EDTA solution (Sigma-Aldrich). HKCSCs have 
been previously described by Celprogen, Inc. and are 
positive for pax2, cd44, cd133, ssea ¾, c-met, oct3/4, aldh 
and telomerase. HKCSCs form tumors in SCID mice and 
is vhl-proficient (data not shown).
The cell lines described below were obtained from 
ATCC. Caki-1, human metastasis of clear-cell renal 
cell carcinoma to the skin, expresses wild-type vhl 
Fig. 1 Schematic presentation of the compared treatment and oxygen groups of HKCSCs
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(vhl-proficient) and forms tumors in immunocompro-
mised mice  (ATCC® HTB-46™), and 769-P, human pri-
mary clear-cell renal cell carcinoma with vhl mutation 
(vhl-deficient), which forms tumors in NOD/SCID mice 
 (ATCC® CRL-1933™), were cultured primarily in mon-
olayer in RPMI 1640 supplemented with GlutaMAX™-I 
(Gibco, Cat. No. 61870036) as well as 10% FBS (PAN 
Biotech, Cat. No. P40-1301) and 1% 100  U/ml penicil-
lin/streptomycin (Life Technologies, Cat. No. 15140122). 
All cells were seeded in T75 flasks and passaged every 
2–3  days. Cells were cultured either in normoxia, in a 
humidified, 5%  CO2- and 20%  O2-containing atmos-
phere or in hypoxic conditions, which were generated in 
a humidified hypoxic incubator with 1%  O2, 5%  CO2 and 
balanced  N2 content.
Cells were visualized using an inverted Olympus micro-
scope with Olympus camera UC30 (Serial No. 14310982) 
and Olympus Entry Cell Sense 1.8.1 software (Serial No. 
PY8HDQECP6Q, core version XV 3.8.).
Tyrosine kinase inhibitors dose response
Clinically relevant maximum doses of sunitinib, sorafenib 
and axitinib were calculated using their peak concen-
trations in serum or plasma. Sunitinib was obtained 
from Sigma-Aldrich (Cat. No. PZ0012). Axitinib was 
also obtained from Sigma Aldrich (Cat. No. PZ0193), 
and sorafenib was obtained from Cayman, Inc. (Cat. 
No. BAY-43-9006). TKIs were first dissolved in DMSO 
(%DMSO < 2% in the final concentration in used media). 
For HKCSCs, 769-P and Caki-1 monolayer cell cul-
tures, following drug concentrations were used in nor-
moxia and in hypoxia for a primary screening of their 
response to drug treatment: sunitinib and sorafenib—
C1 = 0.15 µM (maximum clinically relevant dose admin-
istered to patients) [36, 37],  C2 = 1.5 µM,  C3 = 15 µM, 
 C4  =  150  µM; axitinib—C1  =  0.07  µM (maximum 
clinically relevant dose administered to patients) [38], 
 C2 =  0.15  µM,  C3 =  1.5  µM,  C4 =  15  µM. Subsequent 
choices of doses used for further research resulted from 
an  AlamarBlue® cell lines viability assessment. For resist-
ant HKCSCs cell lines, doses were 10× higher than for 
sensitized HKCSCs cells. For soft agar colony formation 
assay, HKCSCs were treated with sorafenib and axitinib 
in concentrations of 0.15 and 1.5 µM.
769-P and Caki-1 cell lines that did not develop resist-
ance were subjected to treatment only with 0.15  µM of 
both TKIs. Subsequent experiments excluded 769-P and 
Caki-1 as non-resistant cell lines.
AlamarBlue® viability assay and growth curves
Cells were seeded on flat-bottom, 96-well plates (Thermo 
Fisher Scientific, Cat. No. 07-200-90) in the follow-
ing concentrations to achieve their logarithmic phase 
of growth: HKCSCs—1000 cells/well, 769-P—1500 
cells/well, Caki-1—2000 cells/well. Each condition was 
repeated four times.  AlamarBlue® was performed in 
monolayer culture conditions. After 24  h, the medium 
was changed for the appropriate medium containing 
TKI. HKCSCs, 769-P and Caki-1 cell lines were cultured 
in normoxia and hypoxia in the following drug concen-
trations: sorafenib—C1,  C2,  C3,  C4, axitinib—C1,  C2,  C3, 
 C4.  AlamarBlue® viability assay was performed accord-
ing to proper protocol (Life Technologies™, Cat. No. 
DAL1025). Ten microlitre  AlamarBlue® was added to the 
90 µl medium with cells to reach a final concentration of 
10% in each well, as previously described in the literature 
[39]. Cells cultured in medium without treatment were 
used as controls. Growth curves for HKCSCs, 769-P and 
Caki-1 cell lines in normoxia and hypoxia were obtained 
by counting the number of cells per 1 ml each day dur-
ing 6 days of monolayer cell culture in T25 flasks using 
an MOXI™ Z Mini Automated Cell Counter Kit (ORFLO 
Technologies, Cat. No. MXZ001). Percentage of Alamar 
blue reagent’s reduction showed the percentage of cells 
that reduced resazurin to resorufin, which were also met-
abolically active and thus alive.
Soft agar colony formation assay
Colony formation assay was performed on HKCSCs, 
769-P and Caki-1per the STEMTag 96-well Stem Cell 
Colony Formation Assay (Cell Biolabs, Inc., Cat. No. 
CBA-325). Each sample as well as control was prepared 
in triplicate. Pictures of colonies were taken on day 17 
(data not shown) and day 30 under an inverted micro-
scope. The medium was changed every 4–5  days. Cells 
were cultured in normoxia  (pO2 18.75%) and hypoxia 
conditions  (pO2 1%, SANYO MCO-5 M incubator).
Suspension cell cultures
Both clear-cell and papillary RCC were studied using two 
in vitro models (adherent cell culture and colony forma-
tion assay). After noticing the primary resistance to TKI-
like phenomenon in papillary RCC cells, the results were 
confirmed in a third in  vitro model—suspension cul-
ture—using only HKCSCs, which were either untreated 
in normoxia (N) or hypoxia (H), sensitized to sorafenib 
in normoxia (sSN) and to axitinib in hypoxia (sAH) or 
resistant to sorafenib in hypoxia (rSH) and to axitinib in 
normoxia (rAN).
HKCSCs were seeded in T25 polystyrene flasks 
 (Corning®, VWR Cat. No. 29186-010) and cultured in 
StemXVivo Mesenchymal Stem Cell Suspension Medium 
containing EMT (epithelial to mesenchymal transition) 
Supplement (R&D Systems, Cat. No. CCM004), which 
allows for the creation of 3D structures in a suspension 
culture. Cells were cultured as follows:
Page 5 of 18Bielecka et al. Cell Biosci  (2017) 7:71 
1. In normoxia: (a) in 1.5 µM axitinib (cells resistant to 
axitinib in normoxia: rAN), (b) in 0.15 µM sorafenib 
(cells sensitized to sorafenib in normoxia: sSN), (c) 
untreated (normoxia control: N);
2. In hypoxia: (a) in 1.5  µM sorafenib (cells resistant 
to sorafenib in hypoxia: rSH), (b) in 0.15  µM axi-
tinib (cells sensitized to axitinib in hypoxia: sAH), (c) 
untreated (hypoxia control: H).
TKIs were added to the cell culture on day 3 so that 
treatment would impact formed 3D structures. On day 6, 
total protein was isolated.
Muse™ cell cycle and proliferation analysis
To test whether cell cycle is affected in HKCSCs, depend-
ing on oxygen concentration and/or TKI addition, 
untreated, sensitized and resistant cells were exam-
ined both in normoxia and hypoxia. HKCSCs cells were 
seeded in T25 polystyrene flasks as described in “Soft 
agar colony formation assay” of this report. On day 6, 
cells were prepared for Muse™ Cell Analyzer dedicated 
tests: Muse™ Cell Cycle Assay Kit (Merck Millipore, 
Cat. No. MCH100106) and Ki67 Proliferation Assay Kit 
(Merck Millipore, Cat. No. MCH100114) according to 
the manufacturer’s instructions. Collected cell aggregates 
were disrupted using warm accutase prior to permeabi-
lization and fixation. An average of 5000 cells was ana-
lyzed for each condition. Fractions of cells in G0/G1, S 
and G2/M phase as well as fractions of proliferating cells 
were determined on day 6 of cell culture.
Protein isolation and mass spectrometry
Mass spectrometry and western blot analysis were both 
performed on untreated and resistant groups of papil-
lary RCC cells (rAN, N, rSH, H). Briefly, total protein 
was isolated using an RIPA buffer (Sigma-Aldrich, Cat. 
No. R0278) and a Protease Inhibitor Cocktail (Sigma-
Aldrich, Cat. No. P8340). Protein pellet was obtained 
and densed after overnight incubation under acetone 
for mass spectrometry analysis. Three biological rep-
licates were prepared for each analytical group. Protein 
extracts were trypsin digested overnight with 10  ng/µl 
trypsin, then reduced with 5  mM TCEP for 60  min at 
60  °C; cystein thiol residues were blocked with 10  mM 
MMTS for 10 min at room temperature. Resulting pep-
tide mixtures were analyzed with a LC–MS system com-
posed of a nanoHPLC chromatograph (nanoAcquity, 
Waters), directly coupled to the ion source of the LTQ 
Orbitrap Velos working in MS mode (profile datasets, no 
data sequencing). Tandem mass spectrometry for peptide 
sequencing was carried out separately for each group by 
the following procedure: peptide mixtures from all bio-
logical replicates were mixed into a single sample and 
measured in triplicate. To increase the proteome cover-
age, each of the three MS/MS measurements covered 
different m/z ranges: 300–600, 600–900 or 900–2000 Th. 
During further qualitative analysis, data from these three 
measurements were merged into one data file so that 
each analytical group was characterized by a single set of 
proteins. Statistical analysis concerning mass spectrome-
try was performed as described in the protein quantifica-
tion section and described in more detail previously [40].
Protein identification
The acquired MS/MS data were pre-processed with 
Mascot Distiller software (v. 2.5, Matrix Science), and a 
database search was performed using the Mascot Search 
Engine (Matrix Science, Mascot Server 2.4.1) against the 
SwissProt database (release 2015_01, 547,357 sequences; 
194,874,700 residues) restricted to human proteins 
(20,274 sequences). To reduce mass errors, the peptide 
and fragment mass tolerance settings were established 
separately for individual LC–MS/MS runs after a meas-
ured mass recalibration. Other Mascot search settings 
were as follows: enzyme—semiTrypsin, missed cleav-
ages—1; fixed modifications: Methylthio (C); and variable 
modifications: oxidation (M). A statistical assessment of 
peptide assignments was based on the concatenated tar-
get/decoy database search strategy (merged target/decoy 
databases generated with software developed in-house 
[40]). This procedure (Supplementary Method 2) pro-
vided q-value estimates for each peptide spectrum match 
(PSM) in the dataset. All PSMs with q-values > 0.01 were 
removed from further analysis. A protein was regarded 
as confidently identified when at least two peptides of 
this protein were found. Proteins identified by a subset 
of peptides from another protein were excluded from 
analysis. Proteins that exactly matched the same set of 
peptides were combined into a single group (cluster). 
The mass calibration and data filtering described above 
were carried out with Mscan [41] software, developed 
in-house. Peptide/protein identifications derived from 
all analytical groups were exported and used in further 
quantitative analysis.
Protein quantification
Label-free quantification was performed essentially as 
described in [40] using 2D heat-maps generated from 
LC–MS profile datasets and the list of protein/peptide 
identification. The abundance of each peptide was deter-
mined as the height of a 2D fit to the monoisotopic peak 
of the isotopic envelope. Quantitative values were next 
exported into text files, along with peptide/protein iden-
tifications into pairwise statistical analysis using Diffprot 
software [40]. A non-parametric resampling-based test 
statistics with local variance estimate makes Diffprot 
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an appropriate tool for analysis of small scale biological 
experiments. Diffprot was run with the following param-
eters: number of random peptide sets =  106; clustering 
of peptide sets with 80% similarity or higher; and normal-
ization by LOWESS. Results for proteins present in one 
of the analyzed groups in the pairwise comparison were 
manually validated on the heat-maps.
The mass spectrometry proteomics data were depos-
ited to the ProteomeXchange Consortium [42] via the 
PRIDE partner repository using the dataset identifiers 
XD002600 and https://doi.org/10.6019/pxd002600*.
Electrophoresis and western blotting
HKCSCs cells cultured in T25 flasks as described in “Sus-
pension cell cultures”. For clear-cell RCC positive control, 
769-P (primary ccRCC) and Caki-1 (ccRCC metastatic) 
cells were cultured in T75 flasks in monolayer. Cells were 
collected, washed once in PBS and lysed in 50 µl of RIPA 
buffer. Undissolved proteins were pelleted and protein 
concentration in lysates was measured with BCA assay 
(Sigma Aldrich). Ten µg of total proteins from samples 
was dissolved after extraction in 4× Laemmli Sample 
Buffer (60  mM Tris–Cl pH 6.8, 2% SDS, 10% glycerol, 
5% β-mercaptoethanol, 0.01% bromophenol blue, 1:3, 
Amresco Cat. No. J60015). Electrophoresis was per-
formed in polyacrylamide TruPAGE™ Precast 12% gels 
in SDS-PAGE buffer. Subsequently, gels were transferred 
onto Nitrocellulose membranes (biorad, Cat. No. 162-
0094); protein transfer and loading was confirmed by 
Ponceau S staining (Sigma, Cat. No. 09189). After wash-
ing, membrane was blocked with Nonfat Powdered Milk 
(Amresco, Cat. No. M203) and then probed with primary 
antibodies: anti-eif4b (D-4) (Santa-Cruz Biotechnology, 
Inc., Cat. No. sc-376062), anti-map2k1 (Sigma-Aldrich, 
Cat. No. HPA026430). Detection was performed after 
incubation with secondary antibodies: goat anti-rabbit 
IgG–HRP (Cell Signalling Technology, Cat. No. 7074) 
or goat anti-mouse IgG–HRP (Santa Cruz, Cat. No. 
sc-7023), according to recommendations from the manu-
facturer using chemiluminescent horseradish peroxydase 
substrate Luminol (SantaCruz Cat. No. sc-2018) using 
X-ray films. Prism Ultra Protein Ladder (10–245  kDa) 
(Abcam, Cat. No. ab116027) was used for protein size 
estimation. Membranes were scanned and analyzed with 
ImageJ. Band densities were related to Ponceau S staining 
(reference band: 70 kDa).
Real‑time PCR
Cells were cultured in T25 cell culture flasks in monolay-
ers; after 72  h incubation, cells with approximately 80% 
confluence were washed with PBS and covered with Feno-
zol reagent (Total RNA Mini Plus kit, A&A Biotechnol-
ogy, Gdynia, Poland) and RNA isolation was performed 
according to the manufacturer’s protocol. Genomic DNA 
was removed with TURBO DNA-free Kit (Ambion). The 
concentration and purity of RNA were determined by 
measuring the absorption at 230, 260, and 280  nm in a 
Multiskan™ GO Microplate Spectrophotometer. Super-
Script IV First-Strand Synthesis System (Invitrogen) 
was used to generate full-length first strand cDNA from 
total RNA templates using a mixture of oligo-(dT) prim-
ers and hexamers. 2.5 μg of total RNA in 20 μL of reac-
tion mix was used for reverse transcription. Single strand 
complementary DNA (cDNA) generated in rtPCR was 
used as a template for amplification by sqPCR. Real-time 
PCR was performed either with PowerUp SYBR Green 
Master Mix or TaqMan Gene Expression Master Mix 
(both Applied Biosystems) in 7500 Real-Time PCR Sys-
tem (Applied Biosystems) in 96 well plates. Tested genes 
included: flt1 (vegf-1, forward CCTGCAGAGCCAG-
GAATGTAT, reverse GTTGCAGTGCTCACCTCTGA), 
b-raf (forward AAAACACCCATCCAGGCAGG, 
reverse ACTCTCCTGAACTCTCTCACTCA) and c-kit 
(Hs00174029_m1 TaqMan probes). For the confirma-
tion of no contamination with gDNA, minus-RT controls 
were performed for each sample. Data were calculated 
with the 2(−Delta C(T)) method, with normalization to 
mean expression of peptidylprolyl isomerase A (PPIA) 
as a housekeeping gene (sequences for SYBRGreen 
assay: forward CGTGGTATAAAAGGGGCGG, reverse, 
TGTCTGCAAACAGCTCAAAGG, assay Hs01565699_
g1 for TaqMan probes).
Statistical analysis
For Alamar blue statistical measurements, ANOVA test 
was used (all results from all 4 doses from day 1 were 
compared with all results from all 4 doses from day 6 
of the experiment). Statistically significant results are 
marked with * when P  <  0.001. For mass spectrometry 
protein quantification, Diffprot software [40] was used as 
described in “Protein quantification” section. For Muse™ 
flow cytometry analysis, ANOVA test was used (statisti-
cally significant results are marked with * when P < 0.001 
and ** when P < 0.05). Error bars on all figures are pre-
sented as mean ± SD.
Results
Specific oxygen concentration induces different TKI 
response
769-P and Caki-1 cells showed reduced proliferation rates 
under treatment with sunitinib, sorafenib and axitinib in 
monolayer cell cultures both in normoxia and in hypoxia 
(Figs.  2, 3a–d). Proliferation inhibition is dose-depend-
ent, with a significantly ccRCC-toxic minimal dose of 
1.5  nM axitinib for the Caki-1 cell line and a maximal 
dose of 150 µM sorafenib for the 769-P cell line (both in 
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normoxia). Also, papillary renal cancer cells—HKCSCs 
were directly and effectively inhibited with sunitinib in 
monolayer cell cultures. Sunitinib-mediated inhibition 
of HKCSCs proliferation was shown to be dose-depend-
ent with  IC50 ~ 10.5 µM in normoxia and ~ 0.75 µM in 
hypoxia (Fig. 3a–d).
Proliferation inhibition was also shown to be dose-
dependent within ccRCC cell lines, with  IC50 ranging 
from ~ 0.20 to ~ 13.2 µM for 769-P cells cultured in suni-
tinib and for Caki-1 cells cultured in sorafenib, respec-
tively, both in normoxic conditions. However, it should 
be noted that axitinib is more toxic than sorafenib and 
sunitinib; therefore, lower doses are needed to obtain the 
same proliferation reduction rate (around 10× lower in 
the case of axitinib than sorafenib or sunitinib). Thus, 
activity of axitinib against RCC cell lines is higher than 
for sunitinib/sorafenib, reaching  IC50 at the concentra-
tion of minimum 70  nM (769-P in hypoxia) and maxi-
mum of ~ 0.13 µM (Caki-1 in hypoxia).  IC50 was counted 
for day 6 of the 2D cell culture. All results reached statis-
tical significance (P < 0.001).
We have observed that papillary RCC HKCSCs cells 
possibly developed primary-like resistance phenomenon 
to sorafenib due to hypoxic conditions (rSH) and to axi-
tinib in standard oxygen concentration (rAN). HKC-
SCs were not resistant to axitinib in hypoxia and thus 
remained sensitive (sAH). HKCSCs exhibited the same 
relationship with sorafenib in normoxia (sSN). Sorafenib 
and axitinib effectively inhibited the growth of primary 
and metastatic clear-cell renal cell carcinoma cell lines in 
normoxia and hypoxia, but pRCC stem-like cells’ growth 
was inhibited in an oxygen-dependent manner (Fig. 3d).
Stem cell colony formation assay was performed only 
with sorafenib and axitinib to confirm the impact of 
oxygen concentration on renal cancer cells’ response to 
tyrosine kinase inhibitors. Regardless of oxygen concen-
tration, HKCSCs, 769-P and Caki-1 formed colonies if 
no TKI treatment was applied, however, hypoxic colo-
nies were in general smaller and did not develop necrosis. 
Cells inside the colonies were living cells based on Neu-
tral Red uptake (data not shown). Colonies formed by 
Caki-1 were of larger volume but in smaller quantity than 
colonies formed by 769-P cells. The highest number and 
largest size of colonies were observed in the HKCSC cul-
ture. 769-P and Caki-1 cell lines cultured with sorafenib, 
and axitinib had a reduced size of colonies and under-
went cell death, whereas resistant HKCSCs colonies were 
still increasing in size and number on day 30, when the 
cell culture was terminated as innumerable live colonies 
were formed (based on Neutral Red uptake, data not 
shown) (Fig. 4).
Hypoxia slightly decreased the size and amount of 
colonies that were not subjected to TKIs and signifi-
cantly decreased the size and amount of axitinib but not 
sorafenib-treated 769-P colonies. Interestingly, Caki-1 
colonies behaved exactly the opposite; under hypoxic 
conditions, the size and amount of sorafenib, but not axi-
tinib-treated colonies, were visibly decreased.
In suspension culture (the second 3D model) in which 
only HKCSCs were used to investigate the effect of 
hypoxia on TKI-treated RCC cells in another 3D in vitro 
model, multiple aggregates both before and after TKI 
treatment were formed. Hypoxia slightly decreased 
the size and amount of cell aggregates–interestingly, 
three-dimensional structures were darker in normoxia, 
which suggested necrosis but it was not confirmed by 
Fig. 2 HKCSCs papillary stem-like cell line has higher proliferation 
rate than 769-P and ACHN clear-cell RCC cell lines both in normoxia 
(a) and hypoxia (b) culture conditions. Living cells were counted 
using Bürker chamber during 6 days. Those results are confirmed by 
% of Alamar blue® reduction in HKCSCs, 769-P and Caki-1 untreated 
cell lines in normoxia vs hypoxia (c). Error bars presented as ± SD
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Fig. 3 Cell viability by Alamar blue® of HKCSCs, 769-P and Caki-1 cells treated with various doses of sunitinib (a) reduces overtime. Only HKCSCs are 
resistant to sorafenib in hypoxia, marked rSH (b) and to axitinib in normoxia, marked rAN (c) while 769-P and Caki-1 remain sensitive to treatment as 
indicated for 6 days (d). Graphs show the % of Alamar blue® reduction which indicates the number of living (metabolically active) cells. Statistically 
significant results are marked with * when P < 0.001 (ANOVA test). Two graphs marked with a square show resistant cell lines. Error bars presented 
as ± SD
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Neutral red uptake (data not shown). The size of aggre-
gates did not change or decreased slowly in TKI resist-
ant cells (rAN, rSH), while in untreated cells the number 
of aggregates was stably increasing and in sensitized cells 
(sSN, sAH) a reduction in the number of aggregates was 
observed (Fig. 5).
Oxygen tension regulates renal cell carcinoma 
proliferation and viability
Hypoxia was shown to reduce RCC cells’ prolifera-
tion rate and viability in 2D and 3D cell culture models. 
HKCSCs, 769-P and Caki-1 cells cultured in monolayer 
in hypoxia, irrespectively of TKI treatment, showed a 
reduced rate of proliferation in comparison to cells cul-
tured in normoxic conditions as shown by resazurine-
based viability test (Fig. 3b–d). This effect was confirmed 
with enumeration of live HKCSCs, 769-P and Caki-1 cells 
in the 2D culture where all cells reached higher number 
in normoxia (Fig. 2a) than in hypoxia (Fig. 2b). Prolifera-
tion rate was also defined by Ki67 expression in suspen-
sion HKCSCs cultures. HKCSCs cultured in normoxia 
were Ki67 positive (Ki67+) in 87% in comparison with 
HKCSCs, U, 
N, 2D
HKCSCs, U, 
H, 2D
769-P, U, 
N, 2D
769-P, U, H, 
2D
Caki-1, U, N, 
2D
Caki-1, U, H, 
2D
1. U, N, 
HKCSCs [N]
2. U, H, 
HKCSCs [H]
7. U, N, 
769-P
8. U, H, 769-
P
13. U, N, 
Caki-1
14. U, H,
Caki-1
3. S, N, 0.15 
µM HKCSCs 
[sSN]
4. S, H, 1.5 
µM, HKCSCs 
[rSH]
9. S, N,
0.15 µM, 
769-P [s]
10. S, H,
0.15 µM,
769-P [s]
15. S, N, 
0.15 µM, 
Caki-1 [s]
16. S, H,
0.15 µM, 
Caki-1 [s]
5. A, N, 1.5 
µM HKCSCs 
[rAN]
6. A, H, 0.15 
µM HKCSCs 
[sAH]
11. A, N, 
0.15 µM 
769-P [s]
12. A, H, 
0.15 µM 
769-P [s]
17. A, N, 
0.15 µM 
Caki-1 [s]
18. A, H, 
0.15 µM 
Caki-1 [s]
Fig. 4 HKCSCs cells are resistant to sorafenib in hypoxia and to axitinib in normoxia. Hypoxia decreases the amount of colonies visible in 96-well 
plates. Representative images of colonies (performed in triplicate). Magnification 4×, scale bar = 200 µm. The scheme of the figure is shown below. 
Above 2D monolayer cell culture phenotypic view is presented for comparison. U untreated cells, N normoxia, H hypoxia, r resistant cells, s sensi-
tized cells, A axitinib, S sorafenib. Resistant HKCSCs are marked with a red square
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HKCSCs cultured in hypoxia—74%, irrespective of TKI 
treatment (Fig.  6a, b). HKCSCs had the highest prolif-
eration rate compared with 769-P and Caki-1 cell lines; 
clear-cell renal cancer cells had a proliferation rate of 
about 28% lower than HKCSCs, in both oxygen levels 
(Fig. 6a, b).
Tyrosine kinase inhibitors resistance–related response 
in renal cancer stem cells
Reduced proliferation of HKCSCs cells in hypoxic con-
ditions was observed alongside an increase in the num-
ber of quiescent (Ki67−) cells and cells arrested in the S 
phase. In sorafenib-resistant cells (rSH) in hypoxia, the 
percentage of Ki67− cells was lower than in untreated 
hypoxic cells (H). In axitinib-resistant cells in normoxia, 
more cells expressed Ki67 and entered G1 phase in com-
parison to non-treated cells (rAN vs N). Sorafenib-sen-
sitive cells (rSH) in normoxia displayed S phase arrest 
upon treatment. Differences in HKCSCs cell cycling were 
found between normoxic and hypoxic cells, irrespectively 
of TKI treatment. In the case of sorafenib, hypoxic condi-
tions promoted cell survival as opposed to axitinib treat-
ment for which low oxygen pressure sensitized cells to 
treatment which was shown in 2D cell cultures (Fig. 3d) 
as well as in soft agar suspension culture, where red 
squares show resistant cells (see Fig. 4). Also, percentage 
of cells in G1 phase is the highest in resistant cells—rAN 
(Fig. 7a), as well as significantly higher percentage of G0/
G1 cells was noticed for resistant than for sensitized cells 
(Fig. 7b, c).
Elevated map2k1 expression in hypoxia compared 
to normoxia in TKI treated HKCSCs cells
Dual specificity mitogen-activated protein kinase 1 
(encoded by map2k1 gene) protein was detected on high 
level in HKCSCs, characterized by a different reaction to 
TKIs depending on pO2. In 769-P the protein expression 
was much lower, while in Caki-1 cells the protein could 
not be detected (Fig.  8). Additionally, elevated expres-
sion of map2k1 was observed in HKCSCs treated with 
tested drugs in hypoxia, while in normoxia sorafenib 
and axitinib weakly altered the level of the protein. This 
protein was previously reported in RCC [43, 44]. This 
finding corresponds to the fact that map2k1 is a mek-1 
kinase targeted by sorafenib; until now it was known that 
sorafenib does not inhibit mek-1 kinase activity in vitro 
[13]. Map2k1 was detected only in hypoxic sample in 
mass spec analysis (Table 1).
Reduced eif4b expression in hypoxic HKCSCs cells
Also eif4b had the strongest expression in HKCSCs. 
In normoxic cells resistant to axitinib the level of pro-
tein was upregulated, while sorafenib decreased it. In 
all tested hypoxic samples the expression of eif4b was 
strongly diminished (Fig.  8). In total, hypoxic effect 
is similar in both proteins—while it decreases the 
Fig. 5 Heterogenous aggregate formation in suspension culture of HKCSCs before protein isolation for mass spectrometry and Western blotting at 
day 6 of the culture prove resistance of HKCSCs to sorafenib in hypoxia and axitinib in normoxia. Reduced proliferation rates in lower oxygen ten-
sion is shown. Resistant HKCSCs are marked with a black square. Magnification: 4×, scale bar = 200 µm
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Fig. 6 Reduced number of proliferating HKCSCs cells in hypoxia compared to normoxia according to flow cytometry histograms gated on Ki67+ 
cells (a). Bar plots are presented (b). Error bars presented as mean ± SD
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Fig. 7 % of  G1 HKCSCs cells counted on the basis of the equation:  G1 = (G0/G1 − G0:Ki67−) show  G1 HKCSCs cells (a) and percentage of HKCSCs 
cells, resistant, sensitized and untreated with sorafenib and axitinib entering each of cell cycle phases  (G0/G1, S.  G2/M) (b). Bar plots are presented (c). 
Error bars presented as mean ± SD. Statistically significant results are marked with * when P < 0.001 and ** when P < 0.05 (ANOVA test)
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expression of eif4b protein regardless of TKI treatment, 
and decreases the expression of map2k1, in the case of 
map2k1 both TKIs were able not only to restore it, but 
also to even elevate it.
Expression of TKI targets in RCC cells
Tyrosine kinase inhibitors therapeutical effect in solid 
tumors is primary mediated by the action of the drugs 
on endothelial cells as anti-angiogenic therapy. How-
ever, direct effects of these drugs on cancer cells have 
been reported previously [20, 35]. Yet, the mechanism 
of this phenomenon is not clear. Therefore, we checked 
whether studied RCC cell lines express some of the genes 
targeted by tested TKIs. Since braf and c-kit are targeted 
by sorafenib but not by axitinib, and vegfr-1 is targeted 
by axitinib but not by sorafenib, those were receptors of 
choice when assessing the receptor repertoire expres-
sion. No detectable expression of each tested genes was 
observed in HKCSCs on the level of transcript. In our 
preliminary research, we have detected several surface 
receptor markers expression in HKCSCs using Real-time 
PCR method, i.e. cd133 and cd105 under sorafenib treat-
ment and without treatment in normoxia and hypoxia 
(data not shown). 769-P cells showed higher level of b-
raf and c-kit than Caki-1 cell line, while flt1 (also called 
vegfr-1 gene) expression dominated in metastatic cell line 
(Fig. 9).
Discussion
Current availability of several effective agents allowed 
an extended OS (overall survival) rate in RCC patients, 
but mostly in patients with clear-cell RCC [16]. In our 
study, in 2D models, hypoxia does not alter cell morphol-
ogy, but in the 3D level hypoxia reduces 3D structures’ 
amount and volume leaving the cells inside the 3D struc-
ture alive. Since the cells’ lysosomes incorporated Neu-
tral Red stain, alive cells are present inside cell aggregates 
[45]. In such oxygen-restricted conditions, papillary renal 
Fig. 8 Bar graphs represent relative band intensity of map2k1 and eif4b. Quantified mean protein value is relative to Ponceau which was used for 
normalization. To account for the difference in protein loading during the experiment, the percentage of regulation was calculated after the inten-
sity of each band was adjusted according to its respective Ponceau band intensity using the ImageJ 2.1.4.7. software (National Institutes of Health). 
Representative western blots are depicted, showing map2k1 and eif4b expression in HKCSCs untreated, resistant and sensitized cells in normoxia 
and hypoxia. Error bars presented as mean ± SD
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cell carcinoma cells develop primary-like resistance to 
sorafenib and alter its cell cycling and expression of cru-
cial proteins, which have been shown in this study. More-
over, hypoxia causes papillary RCC cells (HKCSCs) to 
behave differently under sorafenib and axitinib treatment 
in three independent cell culture models which may sug-
gest that those cells adapt to the restricted niche and are 
predetermined to form a tumor.
Herein, altered protein expression was mainly observed 
in cells cultured in lower oxygen tension regardless of 
TKI treatment and regardless of whether papillary renal 
cancer cells developed resistance (Table  1). Therefore, 
it seems that the main factor contributing to protein 
in  vitro expression switch is low oxygen tension rather 
than drug treatment. On the other hand, in papillary RCC 
resistant to sorafenib in hypoxia, map2k1 expression was 
highly elevated when compared to untreated and sensi-
tized samples. We have yielded similar results in four bio-
logical repeats (data not shown). Nonetheless, our main 
finding was that although hypoxia decreased the expres-
sion of map2k1, a mek1 kinase, the treatment with axi-
tinib and sorafenib has on the contrary increased map2k1 
expression. Resistant cells to sorafenib in hypoxia had the 
highest map2k1 expression level. Such phenomenon was 
already presented in the literature [46]. Overall, it seems 
that both resistant and sensitized phenotypes of HKCSCs 
cells up-regulated this protein.
Since map2k1 is responsible for signal transduction, it 
possibly directed cells observed in G1 phase to synthesize 
and divide—subsequently, the cells halted the prolifera-
tion in S phase arrest. It may suggest that this mechanism 
may be responsible for resistant cells’ unique way of sur-
vival, which does not take place in normoxia and in this 
way further studies regarding hypoxia should be imple-
mented while studying drug resistance phenomenon.
Previously described alterations in map2k1 protein 
expression together with eif4b support the hypothesis 
that key proteins expression in hypoxic tumor niche is 
regulated mostly by oxygen tension. These findings sup-
port the crucial role of mek1 kinase may be useful in 
cancer cells response to antiangiogenic agents. It was 
previously reported that inhibition of mek1 in the renal 
cell carcinoma xenograft model with acquired resistance 
to sunitinib successfully improved anti-tumor drug effi-
cacy [47]. Therefore, targeting mek1 may be a promising 
pathway in treating TKI-resistant papillary renal cancer 
patients.
Our results confirm previously published clinical data, 
which showed eifs expression in advanced cancers inter 
alia in renal cell carcinomas [48]. The role of eif4b has 
not been thoroughly investigated until now, nor has the 
effect of tumor hypoxia on its expression and vice versa. 
In our study, overexpression of eif4b was observed upon 
treatment both in axitinib resistant (rAN) and cells sensi-
tized to sorafenib (sSN) in normoxia. Hypoxic conditions 
down-regulated the protein, in consequence attaining 
phenotype sensitive to axitinib. However, hypoxic cells 
retained drug resistance to sorafenib. The activity of eifs 
was previously reported to promote survival of cancer 
cells [49]. Interestingly, the addition of axitinib in resist-
ant normoxic cells elevated eif4b expression, which 
would support the hypothesis that hypoxic conditions 
abrogate eif4b expression regardless of TKI addition.
As a result of hypoxia-response mechanism, metabo-
lism of the cell switches to aerobic glycolysis paral-
lely with high glucose influx and high production of 
Fig. 9 Real-time PCR analysis of TKI receptor targets. Error bars presented as mean ± SD
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lactate, which occurs in cancer cells [50]. Until now, it is 
known that 24% of proteins altered in hypoxia are meta-
bolic [51]. Our study showed that pkm, lhda and aldh2, 
which are all metabolic proteins, were overexpressed in 
hypoxia–cultured papillary HKCSCs regardless of TKI 
treatment, being at the same time underexpressed in 
normoxic groups: rAN, N and sSN. This finding supports 
current results published in the literature [52]. Among 
differentially expressed proteins with statistically sig-
nificant results (P < 0.001* or the protein was identified 
in only one group), we detected those implicated in cell 
cycling and proliferation (cdc5l, srrt, 14-3-3ε), transcrip-
tion and/or translation (bclaf1, hnrnpc) and chromosome 
remodeling (baz1b, smarca5) (Table 1).
What is more, none of the tested TKI targets were 
expressed in HKCSCs so it may be that direct anti-cancer 
effects of sorafenib and axitinib in studied conditions is 
mediated by other receptors. It was reported that most 
TKIs are active also against other, off-target tyrosine 
kinase signalling pathways [53]. In total, the identification 
of hypoxia-dependent RNA–protein complexes such as 
eif4b and map2k1 and their molecular characterization 
in cancer signaling should provide insight into new path-
ways that may modulate translation rates in resistant and 
hypoxic cancer cells [54].
Not only is papillary renal cancer cells’ protein expres-
sion profile affected by hypoxic conditions, but 1%  pO2 
also impacts papillary RCC cells’ proliferation rate, cell 
cycling and response to tyrosine kinase inhibitors, which 
we confirmed in both the 2D and 3D cell cultures. Pap-
illary RCC stem-like cells respond differently to axi-
tinib and sorafenib. These cells are resistant to axitinib 
in normoxia (rAN) and resistant to sorafenib in hypoxia 
(rSH). This is, however, primary resistance, not induced 
by exposing cells to gradually increasing TKI doses, as 
presented in a previous in vitro study on sunitinib in the 
786-O cell line [55].
Hypoxia increases the number of Ki67− cells and cells 
in S phase and decreases the number of cells in  G1 phase. 
We suggest that as a result of hypoxic conditions, cells 
divide at a slower rate and reach a quiescent state  (G0 
phase [61]) or arrest in S phase. We reported an increased 
percentage of only resistant cells (rAN and rSH) entering 
 G1 cell cycle phase and a simultaneous drop of  G0 cells, 
which may suggest that quiescent cells are reentering cell 
cycle as a response to the drugs [56]. At the same time, 
these cells are arrested in the S phase, with no change 
in  G2/M fraction. Interestingly, in sensitized cells (sSN, 
sAH) TKI treatment does not affect the cell cycle.
Slower proliferation rate of hypoxic cells presented in 
this research causes higher cells’ resistance to apoptosis 
and/or necrosis. Cells growth is slower; therefore, cell 
aggregates do not reach the sized of normoxic aggregates, 
allowing hypoxia to reach similar level in each of 3D 
structure site. This slower growth may allow resistant 
cells to adapt even to very rigorous conditions and to 
high drug concentrations, which seems to have much in 
common with the general tumorigenic process.
Conclusions
In conclusion, hypoxia impacts tyrosine kinase inhibi-
tors—treated clear-cell and non- clear-cell renal cancer 
cells, papillary and clear-cell. Stem-like papillary RCC 
cells gain primary-like resistance phenotypic features 
dependent on oxygen concentration as well. Thus, oxy-
gen tension regulates tyrosine kinase as well as RCC cells’ 
proliferation rate, protein and gene expression profile. 
These findings suggest that hypoxia modulates renal can-
cer types’ treatment efficacy, also other than clear-cell, 
which may be primarily investigated in  vitro. Nonethe-
less, there is a need to focus on many potential molecular 
targets both on the in vitro and in vivo level, since protein 
activity in vitro may not recapitulate in vivo conditions, 
as in the map2k1 case. We can also hypothetise that 
map2k1 may play a role in hypoxia-mediated resistance 
to sorafenib, while eif4b expression may have its role in 
resistance to axitinib as observed in normoxia.
Nonetheless, protein expression profile needs to be 
double-checked in laboratory conditions and in clinical 
trials. To avoid opposite results in vitro and in vivo, nova-
tory hypoxic in vitro models need to be established.
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